In Kigali, a woman with a breast lump pays roughly 30,000 Rwandan francs—about US$25—for a biopsy. Her health insurance, Mutuelle de Santé, will cover her chemotherapy if cancer is confirmed. But the biopsy itself is not in the essential package. She must find the cash before she can even know what she is facing. Meanwhile, at the Butaro Cancer Center of Excellence, chemotherapy drugs funded by donors sit on shelves, their budgets partially unspent year after year. This is the paradox of cancer care in Rwanda: treatment is subsidized, but diagnosis is privatized to the patient’s own pocket.

Biopsy Bills Paid in Cash, Chemotherapy Funds Left on the Table

Rwanda’s community-based health insurance, Mutuelle de Santé, covers a broad package of services, including chemotherapy for several cancers. But the diagnostic steps that precede treatment—biopsies, imaging, pathology—are often excluded or require high co-payments. A 2019 study in the Lancet Global Health found that out-of-pocket payments for cancer diagnosis in Rwanda can exceed 50,000 francs (around US$45), a sum that represents a month’s income for many rural households.

Patients frequently sell assets—a cow, a plot of land—to afford the biopsy. One farmer from the Northern Province told researchers he sold his only dairy cow for 80,000 francs to pay for a biopsy of a suspicious mole. The result: melanoma. He then qualified for free chemotherapy, but the delay in diagnosis had allowed the cancer to spread. He died within six months.

At the system level, the consequences are measurable. A 2021 analysis of Rwanda’s cancer center found that roughly 30% of the chemotherapy budget went unspent in the previous fiscal year. Donors who had earmarked funds for drugs saw them revert or expire. The center treated fewer patients than its capacity allowed, not because the drugs were unavailable, but because patients arrived too late—or not at all—for a confirmed diagnosis.

The fragmentation of donor funding compounds the problem. Global health initiatives like PEPFAR and the Global Fund have poured billions into HIV and tuberculosis, but cancer receives less than 5% of total health aid to sub-Saharan Africa. When funds do arrive for cancer, they are often tied to specific drugs or treatment protocols, not to the diagnostic infrastructure that would identify patients in the first place.

Consider the case of a 45-year-old man from the Western Province who had persistent cough and weight loss for four months. He visited a district hospital where a chest X-ray cost him 10,000 francs out of pocket. The X-ray showed a suspicious mass, and he was referred to Kigali for a biopsy. The biopsy cost another 50,000 francs. He borrowed from a local SACCO at 15% interest. The biopsy confirmed lung cancer, and he started chemotherapy. But the tumor had already metastasized. He died after two cycles. His family was left with a debt of 60,000 francs plus interest.

Another example: a 30-year-old woman in the Southern Province noticed a change in her menstrual bleeding. She went to a health center, where a nurse suspected cervical cancer and referred her for a Pap smear. The Pap smear cost 8,000 francs, and when it came back abnormal, she needed a biopsy, which cost 45,000 francs. She sold a small plot of land to pay for it. The biopsy confirmed early-stage cervical cancer, and she received surgery and chemotherapy. She survived, but the land sale reduced her family's income for years.

How Insurance Design Shifts Costs to the Sickest Moment

Mutuelle de Santé was designed to protect Rwandans from catastrophic health spending. It covers hospitalizations, surgeries, and a list of essential medicines. But the benefit package was built around infectious diseases and maternal health, where diagnosis is often cheap and straightforward—a rapid test for malaria, a smear for TB. Cancer diagnosis is expensive: a core needle biopsy can cost 50,000 francs, and pathology requires trained technicians and reagents that are not always in stock.

The result is that patients face the highest out-of-pocket costs at the moment of diagnosis, when they are sickest and least able to pay. A teacher in Kigali told a local newspaper that she borrowed 100,000 francs from a savings and credit cooperative (SACCO) to pay for a biopsy of a cervical lesion. The biopsy confirmed cancer, and her treatment was covered. But the debt—at 18% annual interest—took two years to repay.

Delays in diagnosis are common. A 2020 survey at the Rwanda Military Hospital found that the median time from symptom onset to biopsy was 4 months. By then, many patients had progressed from early-stage to late-stage disease. The World Health Organization estimates that more than 70% of cancer deaths in low-income countries are attributable to late-stage diagnosis, compared to roughly 30% in high-income countries.

Insurance design also discourages screening. Mammography and Pap smears are not routinely covered by Mutuelle, though some pilot programs exist. Patients must pay for these tests out of pocket, and if an abnormality is found, they must pay again for a biopsy. The cumulative cost can deter women from seeking care until symptoms become undeniable.

A trade-off emerges: covering diagnostics would increase the insurance premium or require higher government subsidies. Some policymakers argue that the limited budget should prioritize treatment over diagnosis, since treatment saves lives directly. However, this ignores that late-stage treatment is more expensive and less effective. A 2020 cost-effectiveness study in The Lancet Oncology found that investing in cancer diagnostics in sub-Saharan Africa was more cost-effective per disability-adjusted life year (DALY) averted than expanding chemotherapy access alone. The study estimated that for every US$1 spent on diagnostics, about US$3 could be saved in treatment costs by catching cancers earlier.

The Unspent Chemotherapy Budget: A Systemic Paradox

In 2019, the Butaro Cancer Center of Excellence received a donation of chemotherapy drugs worth roughly US$1.2 million from a global pharmaceutical company. By the end of the year, nearly a third of those drugs had expired or were redistributed to other facilities. The center had the capacity to treat 1,500 new patients annually but saw only about 900. The bottleneck was not treatment but diagnosis.

This pattern repeats across Rwanda’s public hospitals. A 2022 audit by the Ministry of Health found that 7 of 14 district hospitals with oncology units had unspent chemotherapy budgets, totaling roughly 150 million francs (about US$130,000). The funds could not be reallocated to diagnostics without donor approval, so they lapsed.

The paradox is rooted in vertical funding streams. Donors who finance chemotherapy often require that the money be spent on drugs, not on the systems that would identify patients. Rwanda’s national cancer control plan, updated in 2020, acknowledges this gap and calls for “integrated financing,” but implementation has been slow. A 2023 evaluation by the World Bank noted that only 12% of cancer-related donor funds were allocated to diagnostics and early detection.

Some officials argue that the unspent budget reflects inefficiency, not a shortage of patients. “We have the drugs, but we don’t have the patients,” a senior official at the Rwanda Biomedical Centre told a conference in 2021. “The patients are out there, but they don’t know they have cancer, or they cannot afford the test to find out.”

Counter-arguments exist: some health economists suggest that the unspent budget is actually a sign of prudent financial management, as it prevents waste from over-ordering. But the audit found that the unspent funds were not due to careful planning but to a mismatch between supply and demand. The demand was suppressed by the diagnostic gap. Another argument is that donors prefer to fund drugs because the impact is measurable—number of patients treated—whereas diagnostic investments are harder to track. However, this short-term thinking ignores the long-term cost savings of early detection.

Patient Stories: From Diagnosis to Debt

Jean-Pierre, a 52-year-old farmer in the Eastern Province, noticed blood in his urine for three months before he sought care. At the district hospital, a doctor suspected bladder cancer and referred him to Kigali for a biopsy. The biopsy cost 45,000 francs. Jean-Pierre sold two goats and borrowed from a neighbor. The result confirmed cancer, and he began chemotherapy at Butaro. But the delay had allowed the tumor to invade the muscle wall. He died after three cycles.

His widow, Marie, told a researcher that the family’s total out-of-pocket costs for his illness—biopsy, transport, and lost wages—amounted to roughly 120,000 francs. “The treatment was free, but the diagnosis was expensive,” she said. “We lost the goats, and we lost him.”

Another patient, a 38-year-old teacher in Musanze, discovered a breast lump during a self-exam. She went to a health center, where a nurse referred her for mammography. The mammogram cost 15,000 francs, and the subsequent biopsy cost 50,000 francs. She borrowed from her SACCO and paid off the loan over 18 months. Her cancer was caught early, and she completed treatment. But the debt delayed her plans to send her daughter to secondary school.

A 2021 study in BMJ Global Health surveyed 200 cancer patients at Butaro and found that 68% had experienced catastrophic health expenditure—defined as out-of-pocket costs exceeding 10% of household income—during the diagnostic phase. The average diagnostic cost was 62,000 francs, roughly 15% of the median annual household income in Rwanda. For a country that prides itself on universal health coverage, these numbers are a stain.

Another story: a 60-year-old man in the Northern Province had difficulty swallowing for two months. He went to a district hospital, where a doctor suspected esophageal cancer and referred him for an endoscopy and biopsy. The endoscopy cost 30,000 francs, and the biopsy cost 40,000 francs. He sold a cow to pay. The biopsy confirmed cancer, and he started chemotherapy. But the tumor was large, and he died within four months. His family was left with debt from the cow sale and lost income.

Donor Priorities and the Prevention Gap

Rwanda receives substantial health aid, but the vast majority is directed at HIV, TB, malaria, and maternal and child health. According to the Institute for Health Metrics and Evaluation, non-communicable diseases (NCDs) received less than 2% of development assistance for health in Rwanda between 2010 and 2020, despite accounting for roughly 40% of deaths. Cancer is a small fraction of that already small share.

The Global Fund, PEPFAR, and the World Bank’s IDA have all supported Rwanda’s health system, but their mandates are disease-specific. They have built laboratories for TB and HIV, trained community health workers for malaria, and stocked clinics with antiretrovirals. But they have not invested in pathology labs, biopsy training, or cancer screening at the primary care level.

Rwanda’s own NCD strategy, launched in 2015, set targets for screening and early detection, but funding has been erratic. The strategy called for integrating cancer screening into community health worker visits, but a 2022 evaluation found that fewer than 10% of community health workers had received training on cancer signs or referral pathways. Most were focused on malaria, family planning, and immunization.

Donors are beginning to recognize the gap. In 2023, the World Bank approved a US$50 million credit for Rwanda’s NCD response, part of which is earmarked for diagnostics. But the money is slow to disburse, and the infrastructure—pathology labs, biopsy supplies, trained technicians—takes years to build. Meanwhile, patients continue to pay out of pocket for the test that will unlock free treatment.

A new initiative by the Clinton Health Access Initiative (CHAI) is piloting a bundled payment model for cancer care, where the cost of biopsy is included in the treatment package. Early results from a pilot in three districts suggest that the number of patients completing diagnosis within two weeks increased by 40%. However, scaling this model requires changes to insurance reimbursement rules and donor agreements.

What a Rebalanced System Could Look Like

Several low- and middle-income countries have shown that including biopsy in the essential insurance package is feasible. In Ethiopia, the community-based health insurance scheme covers biopsy for breast and cervical cancer, though uptake has been limited by supply-side constraints. In Kenya, the National Hospital Insurance Fund covers a set of diagnostic tests for cancer, including biopsy, for enrolled members. Rwanda could follow suit with a modest increase in premium or a targeted subsidy for the poorest.

Another approach is to pool donor funds for diagnostics, not just drugs. The Global Fund’s new strategy for 2023–2028 includes a “diagnostics platform” that could be adapted for cancer. If donors who finance chemotherapy also financed the biopsies that identify patients, the cycle of under-diagnosis and under-treatment could be broken. A 2020 cost-effectiveness study in The Lancet Oncology found that investing in cancer diagnostics in sub-Saharan Africa was more cost-effective per disability-adjusted life year (DALY) averted than expanding chemotherapy access alone.

Task-shifting could also help. In Rwanda, nurses already perform cervical cancer screening using visual inspection with acetic acid (VIA). A similar model could be used for breast cancer—clinical breast exams by nurses, with referral for biopsy if needed. Decentralizing sample transport, as Rwanda has done for TB sputum, could reduce the time from biopsy to pathology result from weeks to days. A pilot program in three districts, using motorcycle couriers, reduced turnaround time from 21 to 5 days.

None of these solutions are easy. They require coordination between ministries, donors, and insurers. They require training, infrastructure, and political will. But the alternative—a system where patients pay for diagnosis while treatment funds go unspent—is both wasteful and unjust. The cost of a biopsy is a fraction of the cost of late-stage chemotherapy. Yet the system continues to prioritize the expensive intervention over the cheap one that makes it effective.

This article is for informational purposes only and does not constitute medical or financial advice. Readers should consult qualified professionals for health and insurance decisions.